Supplementary Information

Title: Anti-LRP/LR antibody IgG1-iS18 rescues cells from $A\beta_{42}$ induced cytotoxicity

Authors: Bianca Da Costa Dias[1], Katarina Jovanovic[1], Danielle Gonsalves[1], Kiashnee Moodley[1], Uwe Reusch[2], Stefan Knackmuss[2], Clement Penny[3], Marc S. Weinberg[4] Melvyn Little[2] & Stefan Weiss[1*]



Figure S1| The effects of Antibody treatment on cellular viability. Cellular viability as determined by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (1 mg/ml) assay was assessed in HEK293FTcells (**a**), N2a cells (**b**) and SHSY5Y cells (**c**) post 48h incubation in the absence of antibody, in the presence of Dulbecco's Phosphate Buffered Saline (D-PBS) (antibody carrier) or either 50µg/ml IgG1-iS18 or IgG1-HD37. The no antibody control was set to 100%. Error bars represent sd. n=3, $p>0.05$; Student's *t*-test.



Figure S2| Cellular effects of mock and shRNAscr-transfection of HEK293 cells. HEK293 cells were either untreated (non-transfected), transfected with the scrambled shRNA control (shRNAscr) or mock-transfected (in which the *Trans*IT®-LT1 (Mirus) transfection reagent was administered to cells in the absence of a plasmid). The cellular effects of the transfection procedure and shRNAscr were assessed 72h post transfection by both MTT (**a**) and BrdU assays (**b**), to evaluate the consequences thereof on cell viability and proliferation, respectively. Error bars represent sd. n=3, $p>0.05$; Student's *t*-test